Pexelizumab: Phase III

Preliminary results from the double-blind, placebo-controlled U.S. Phase III PRIMO-CABG trial in 3,000 patients showed that pexelizumab missed the primary

Read the full 209 word article

How to gain access

Continue reading with a
two-week free trial.